Atossa Therapeutics Board Approves CVR Tied to Rare Pediatric Disease Voucher (ATOS)

Atossa Therapeutics (ATOS) said its board approved issuing one contingent value right per common share, tying holders to potential proceeds from the company's first qualifying Rare Pediatric Disease Priority Review Voucher. The stock closed up 1.53% at $1.99 on Tuesday, September 29, 2026. Under the structure, CVR holders would collectively receive 25% of net proceeds from a qualifying PRV monetization, capped at $50 million. The CVRs would remain attached to ATOS shares and not trade separately. Atossa holds FDA Rare Pediatric Disease designations for lead candidate (Z)-endoxifen in Duchenne muscular dystrophy and McCune-Albright syndrome. No product candidate has been approved and no PRV awarded to date, so any payment remains contingent. The CVRs expire if no qualifying voucher is awarded by December 31, 2036, unless extended. Atossa reported $26.20 million in cash, cash equivalents and restricted cash as of June 30, 2026.